Craig S. Taylor, Ph.D., President and CEO,
has been President, Chief Executive Officer and a Director since September 2009. Dr. Taylor was working as a management consultant prior to joining the Company, and had also worked as a management consultant from 1994 to 1996. He was previously the CEO of a small private biotech company from 2007 to 2008. Prior to his tenure at Adams Street Partners, LLC where he was Partner, Direct Venture Capital Investments from 2000 to 2006, Dr. Taylor served as Associate Director of Business development for G.D. Searle (now part of Pfizer) from 1996 to 2000. Prior to joining Searle in a business capacity, he served as a Senior Research Biochemist, Project Manager at Abbott Laboratories (NYSE: ABT) in the Diagnostic Division from 1990 to 1993. Dr. Taylor’s career has blended his scientific and business experience, building from his formal education, having earned both a Ph.D. at Georgetown University, School of Medicine and an MBA from the University of Chicago, Booth School of Business.
Peter Davies, Ph.D., has been involved with the Company since 1992 as the founding scientist of the Company's core Alzheimer’s technology. Dr. Davies joined the faculty of the Department of Pathology at the Albert Einstein College of Medicine in 1977, three years after beginning his research on Alzheimer's disease. A decade later, he was named the college's Judith and Burton P. Resnick Professor of Alzheimer’s Disease Research. His research has guided APNS in their activities directed toward development of solutions for neurodegenerative diseases. Dr. Davies has co-authored well over 100 scientific papers in the field of Alzheimer’s research where he is a world-renowned leader. His contributions to AD research have been at the forefront of understanding the pathological mechanisms involved in the formation of neurofibrillary tangles; one of the two hallmark pathologies of AD. The relationship between activation of mitotic mechanisms, tangle formation and neuronal death is a major focus of his current work. Currently Dr. Davies is focusing his expertise and vast knowledge in the AD field towards developing new therapeutics to treat, and better diagnostics for early detection of, Alzheimer’s disease.
BOARD OF DIRECTORS
Ellen R. Hoffing, Chairman, was appointed Chairman of the Board of Directors in December 2007 and was the President and Chief Executive Officer of the Company from August 2006 to September 2009. From 2005 to August 2006, she had been a consultant to healthcare focused companies. In 2005, Ms. Hoffing was Vice President, Strategic Planning at American Pharmaceutical Partners, a publicly traded specialty pharmaceutical company focused on injectable oncology, anti-infective and critical care products. From 2002 to 2005, Ms. Hoffing was Vice President, Renal Pharmaceuticals at Baxter Healthcare, a New York Stock Exchange listed company. From 2001 to 2002, she was Vice President, Strategy and Acquisitions, at Merisant (the maker of Equal®) and from 2000 to 2001, Ms. Hoffing was a strategy and management consultant to healthcare focused companies. Prior to 2000, Ms. Hoffing took on roles of increasing responsibility in her 17 years at the Searle division of Monsanto, which culminated in her position as Vice President, Global Analytics. Ms. Hoffing was appointed to the Board of Directors of Perrigo Company in July 2008.
Edward Ogunro, Ph.D., Director, has been a director of the Company since November 2008. Dr. Ogunro recently retired from his position as Senior Vice President, R&D and Medical Affairs and Chief Scientific Officer at Hospira, Inc. where he was part of the executive management team that transitioned the company from a division of Abbott Laboratories in April 2004 to a successful stand-alone entity. Dr. Ogunro joined Abbott Labs as a Research Biochemist in the Diagnostics Division in June 1982 and took on roles of increasing responsibility including Program Director for AxSym, one of the most successful analyzers in the diagnostic industry. In addition, in his 20 plus years at Abbott Labs, Dr. Ogunro held senior leadership positions including Divisional Vice President, Immunodiagnostics and Chemistry in the Diagnostics Division and Corporate Vice President R&D, Medical and Regulatory Affairs in the Hospital Products Division. Previously, Dr. Ogunro pursued postdoctoral studies and served as an Assistant Professor at Northwestern University Medical School in Chicago.
Gary C. Parks, Director, has been a Director of the Company since November 2008. Since 1993 Mr. Parks has served as the Secretary, Treasurer and Chief Financial Officer of Immtech Pharmaceuticals, Inc., a company dedicated to the discovery and development of therapies to treat infectious diseases affecting the global community. Previously, Mr. Parks held financial operations roles of increasing responsibility including Vice President, Finance at Smallbone, Inc., from 1989 until 1993, Division Controller with International Paper from 1986 to 1989 and Vice President of Serck Baker, Inc., a subsidiary of BTR plc, from 1982 to 1989 and board member of Serck Baker de Venezuela.
David C. Tiemeier, Ph.D., Director, has been a director of the Company since October 2007. He is currently serving as Deputy Director of UChicagoTech, the University of Chicago’s Office of Technology and Intellectual Property. Previously, Dr. Tiemeier pursued postdoctoral studies in molecular genetics at the National Institutes of Health before joining the faculty of the University of California, Irvine, Medical School. He joined Monsanto Co. as the head of Molecular Genetics, and continued his career in Monsanto’s pharmaceutical division as Senior Director of Immunoinflammatory and Infectious Diseases and took on roles of increasing responsibility including General Manager of the Global New Business Franchise and Vice President of Global Business Development. He subsequently held senior positions in Pharmacia Corporation and Pfizer Inc. Following his retirement from Pfizer, Dr. Tiemeier held senior management positions with NeoPharm, Inc., Immtech Pharmaceuticals, Inc. and Kalypsys, Inc.
|
